<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052506</url>
  </required_header>
  <id_info>
    <org_study_id>215HV101</org_study_id>
    <nct_id>NCT01052506</nct_id>
  </id_info>
  <brief_title>BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects</brief_title>
  <official_title>A Randomized, Blinded, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the safety and tolerability of single dose
      of BIIB033 administered to healthy adult volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BIIB033 is an investigational product being developed to promote remyelination in subjects
      with multiple sclerosis (MS). This healthy volunteer study will evaluate safety and
      tolerability of a single dose of BIIB033.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by adverse event monitoring, laboratory assessments and MRI</measure>
    <time_frame>up to 4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability as measured by adverse event monitoring, laboratory assessments and MRI</measure>
    <time_frame>up to 4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>BIIB033 serum pharmacokinetics levels</measure>
    <time_frame>up to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BIIB033 serum antibodies levels</measure>
    <time_frame>up to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory blood, urine and CSF biomarkers</measure>
    <time_frame>up to 4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of saline solution (8 cohorts IV; 1 cohort SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIIB033</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, escalating doses of BIIB033 (8 cohorts IV; 1 cohort SC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB033</intervention_name>
    <description>Single, escalating doses of BIIB033 (8 cohorts IV, 1 cohort SC)</description>
    <arm_group_label>BIIB033</arm_group_label>
    <other_name>Anti-LINGO-1 antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose of placebo comparator (8 cohorts IV, 1 cohort SC)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be in good health

          -  BMI of 18-30kg/m2

          -  Contraception required for at least 6 months after study drug administration

        Exclusion Criteria:

          -  History of clinically significant disease or lab values

          -  Females of childbearing potentials

          -  Contraindication to brain MRI and/or lumbar puncture

          -  Treatment with any prescription medication within the 28 days prior to study entry

          -  Treatment with any over-the-counter products, including herbal and/or alternative
             health preparations and procedures within the 14 days prior to study entry

          -  Regular use of any tobacco product within 3 months prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tran JQ, Rana J, Barkhof F, Melamed I, Gevorkyan H, Wattjes MP, de Jong R, Brosofsky K, Ray S, Xu L, Zhao J, Parr E, Cadavid D. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflamm. 2014 Aug 21;1(2):e18. doi: 10.1212/NXI.0000000000000018. eCollection 2014 Aug.</citation>
    <PMID>25340070</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2010</study_first_submitted>
  <study_first_submitted_qc>January 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2010</study_first_posted>
  <last_update_submitted>January 5, 2017</last_update_submitted>
  <last_update_submitted_qc>January 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

